Navigation Links
Micromet Announces Proposed Public Offering of Common Stock
Date:3/9/2010

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials.  Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding the proposed offering of our securities, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include uncertainties regarding the market conditions and investor interest in the offering and other risks identified in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2009. We caution you not to place undue reliance on any forward-looking statements, which
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
2. Final Data from Phase 2 Study Confirm High Response Rate of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
3. Bayer Schering Exercises Option to Develop Solid Tumor BiTE Antibody with Micromet
4. Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009
5. Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
6. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
7. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
8. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
9. Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203
10. Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
11. Micromet Key Events for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held medical ... has been appointed Interim Chief Executive Officer of the ... succeeds Ken Berger .  "The Board of Directors ... leading ConvaTec over the past three years," said ... Directors.  "We are confident that the company is well ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 22, 2014  Mark Farrah Associates (MFA), ... summary of the 2015 marketplace exchange projections and ... According to a recent ASPE (Office ... Department of Health and Human Services) report, an ... medical plans through the Marketplace as of October ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... N.J., Sept. 2 ConvaTec, a world-leading developer and ... care, announced today the introduction of a new, narrower ... Strengthening Fibers, now available in the U.S. and select ... exuding chronic and acute wounds. The new dressing, half ...
... Millennium Research Group (MRG), the global authority on medical ... will be driven by strong surgeon acceptance and adoption, ... Japanese surgeons are increasingly adopting anatomic, locking ... and Synthes, Locking Compression Plates , in order ...
Cached Medicine Technology:ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 2ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 3ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing 4Surgeons Drive Plate and Screw Market to Over $170 Million in Japan by 2014 2
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 DW-InductionHeating.com (DaWei ... in designing, researching and developing, producing and marketing of ... of the business announces their new series of ... manager of the company, induction brazing refers ... a special filler material and heat. The manager says ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... ... rage. Today more than ever, people are turning to books on attaining success to help ... together, a recent discovery by Steve Paris, CEO of Orne Publishing, is about to turn the ... , ...
... As ... complete, three-part, self-treatment acupressure kit for the body. The Kit will include an acupressure ... ... June 28, 2010 -- As of today, the exclusive U.S. distributors of The ...
... for measles, mumps, rubella and chickenpox (MMRV) is associated ... to 2-year-old children compared with same-day administration of the ... varicella (V) vaccine for chicken pox, according to a ... the journal Pediatrics . A febrile seizure is ...
... HealthDay Reporter , SUNDAY, June 27 (HealthDay News) -- ... linked with a predisposition for type 2 diabetes, bringing the ... 38. At this point, the findings don,t mean ... lead to better treatments. "From here, to apply this ...
... ... Tarot Professionals Ltd establishes Tarosophy® Tarot Houses worldwide for ... prepared to warn Tarot readers by highlighting certification scams, bad practice ... Tarot Professionals Ltd continues to introduce innovative Tarot courses – join ...
... 26 Elevated blood levels of high-density lipoprotein (HDL) ... disease, may do the opposite in women with type ... School of Public Health study being presented at the ... The study, abstract number 0098-OR, included 658 men and ...
Cached Medicine News:Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 3Health News:Yantra Mat USA Introduces the Yantra Kit: Bringing the Health Benefits of Acupressure to the Entire Body 2Health News:Combination MMRV vaccine linked with 2-fold risk of seizures 2Health News:Combination MMRV vaccine linked with 2-fold risk of seizures 3Health News:More Genes Implicated in Type 2 Diabetes 2Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 2Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 3Health News:Tarosophy Deals A Fair Hand for All Tarot Seekers 4Health News:Can too much HDL be harmful to women with type 1 diabetes? 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: